Titre :

Motivation to pursue anti-tnf? treatment in patients with crohn''s disease - the space motivation study

Auteur(s) :

D''''amico, Ferdinando [Auteur]
Peyrin-Biroulet, Laurent [Auteur]
Vandromme, Luc [Auteur]
Bouhnik, Yoram [Auteur]
Faure, Patrick [Auteur]
Nahon, Stephane [Auteur]
Hagege, Herve [Auteur]
Hebuterne, Xavier [Auteur]
Benkhalifa, Salim [Auteur]
Nachury, Maria [Auteur]

Titre de la revue :

Digestive and liver disease . official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver

Nom court de la revue :

Dig Liver Dis

Date de publication :

2020-06-09

ISSN :

1878-3562

Mot(s)-clé(s) :

Motivation
Satisfaction of patients with Crohn's disease questionnaire (SPACE-Q)
Treatment adherence
Anti-tumor necrosis factor
alpha Crohn's disease

Discipline(s) HAL :

Sciences du Vivant [q-bio]

Résumé en anglais : [en]

Crohn's disease (CD) is a chronic disorder requiring long-term treatment. However, up to 20% of patients interrupt temporarily or permanently anti-TNFα. Primary aim was to identify internal and external factors influencing ...
Lire la suite >Crohn's disease (CD) is a chronic disorder requiring long-term treatment. However, up to 20% of patients interrupt temporarily or permanently anti-TNFα. Primary aim was to identify internal and external factors influencing patient's motivation to pursue anti-TNFα in active CD. This was a French, multicentre, prospective study enrolling CD patients on anti-TNFα therapy since more than 3 months. Patients completed the Satisfaction of Patients with Crohn's Disease questionnaire (SPACE-Q) and other patient-reported-outcome tools at inclusion visit, and after 6 and 12 months. A total of 274 patients were included: 146 (53.3%) received adalimumab, while 128 (46.7%) infliximab. Most patients (78%) were still treated with anti-TNFα 12 months after enrolment. Patients' perception of necessity (p = 0.01) and concerns (p<0.0001) regarding medication, evaluated through the Belief about Medicines Questionnaire (BMQ), and expectation confirmation towards treatment convenience (p = 0.02), towards efficacy (p = 0.04), and treatment satisfaction (p = 0.03) according to SPACE-Q, correlated with motivation to pursue treatment. Patients with higher treatment satisfaction (p = 0.0004), stronger belief in treatment necessity (p<0.0001) and fewer concerns (p = 0.0002) were more likely to be very motivated. Treatment satisfaction, treatment necessity, and concerns are correlated to motivation to pursue anti-TNFα. Specific questions focused on these patients' perceptions could help physicians to identify patients at risk of non-adherence and prevent therapy interruption.Lire moins >

Langue :

Anglais

Audience :

Internationale

Vulgarisation :

Non

Établissement(s) :

CHU Lille
Inserm
Université de Lille

Collections :

• Institut de Recherche Translationnelle sur l'Inflammation (INFINITE) - U1286

Date de dépôt :

2021-07-06T12:47:47Z